Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹38 Cr
Revenue (TTM)
₹9 Cr
Net Profit (TTM)
₹-8 Cr
ROE
-11.5 %
ROCE
-8.5 %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
44.74
EV/EBITDA
-5.9
Div. Yield
0 %
Debt to Equity
0.2
Book Value
₹6.9
EPS
₹-1.2
Face value
2
Shares outstanding
61,551,907
CFO
₹-21.76 Cr
EBITDA
₹-7.46 Cr
Net Profit
₹-16.25 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vista Pharma
| -23.3 | -9.6 | -23.5 | -43.3 | -9.3 | -7.9 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Vista Pharma
| -31.0 | -23.5 | 24.5 | 14.0 | 1.3 | 1.7 | -66.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vista Pharma
|
6.2 | 38.4 | 8.6 | -7.7 | -106.8 | -17.1 | -- | 0.9 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
1 min read•By Research Desk
Vista Pharmaceuticals Limited manufactures and sells pharmaceutical, medical, and veterinary preparations in India, the United States, and internationally. It offers over the counter and prescription generic drugs consisting of tablets, capsules, and... liquids covering various therapeutic categories. Vista Pharmaceuticals Limited was incorporated in 1991 and is based in Hyderabad, India. Read more
Incorporated
1991
Chairman
Dhananjaya Alli
Managing Director
Murali Meraga
Headquarters
Nalgonda Dist, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Vista Pharmaceuticals Ltd is ₹6.24 (BSE) as of 02-Apr-2026 IST. Vista Pharmaceuticals Ltd has given a return of -9.29% in the last 3 years.
Since, TTM earnings of Vista Pharmaceuticals Ltd is negative, P/E ratio is not available.
The P/B ratio of Vista Pharmaceuticals Ltd is 0.91 times as on 02-Apr-2026, a 71 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
1.46
|
|
2024
|
0.00
|
1.41
|
|
2023
|
0.00
|
1.03
|
|
2022
|
0.00
|
0.96
|
|
2021
|
0.00
|
1.01
|
The 52-week high and low of Vista Pharmaceuticals Ltd are Rs 13.09 and Rs 5.71 as of 04-Apr-2026.
Vista Pharmaceuticals Ltd has a market capitalisation of ₹ 38 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vista Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.39
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.